Determine the Symptom Intensities, Performance and Hopelessness Levels of Advanced Lung Cancer Patients for the Palliative Care Approach

Esra Dogan, MSc, RN¹ and Hanife Ozcelik, PhD²

Abstract
This research was conducted descriptively to determine the symptom intensities, performance and hopelessness levels of advanced lung cancer patients for the palliative care approach. The research sample consisted of 130 patients with advanced lung cancer, who were selected from 600 lung cancer populations in thoracic surgery and intensive care, outpatient chemotherapy, oncology in a university hospital in Turkey. Ethics Committee permission and the patients’ written consent was obtained. Study data were collected face to face between January 2020 and July 2020 using the Edmonton Symptom Assessment System, Karnofsky Performance and Beck Hopelessness Scale. The mean age of the patients was 62.68 ± 8.867, 72.3% were males, and 89.2% were not currently working. The most common symptom in the patients was found to be fatigue 5.46 ± 2.12, worsening in general health and well-being 5.69 ± 1.87, loss of appetite 5.40 ± 2.59, and total symptom score 47.17 ± 19.03. Feelings and expectations about the future 1.40 ± 1.66, loss of motivation 3.43 ± 2.41, hope 2.05 ± 1.75, and total score of hopelessness 7.41 ± 6.01. There was a positive correlation between the patients’ hopelessness level and their symptom burden, and a negative correlation was found with Karnofsky performance (P < .05). A significant difference was found between the patients’ age, months since diagnosis, gender, education and employment status, stage of the disease, presence of metastases and analgesic use, and hopelessness scores (P < .05). It was determined that the symptom burden of patients with advanced lung cancer increased and as their Karnofsky performance decreased, their hopelessness level further increased. Hopelessness scores are affected by the socio-demographic and disease variables of the patients.

Keywords
advanced lung cancer, hopelessness, palliative care approach, symptom burden, performance status, palliative care

Introduction
Lung cancer has a high mortality rate and is among the first causes of cancer-related deaths worldwide.¹,² Patients with advanced lung cancer experience many different physical symptoms, particularly dyspnea, and also frequently experience psychological and social problems brought about by the disease and these symptoms.³,⁴ In a study by Sung et al.,⁵ it was discovered that the most common symptoms in patients with advanced lung cancer were fatigue, cough, and dyspnea.⁵ Kapo found that patients with advanced lung cancer often experienced pain, apnea and fatigue; their quality of life was low, and these symptoms affected 65% of the patients.⁶ Wilcock et al.⁷ stated that lung cancer patients are in need of palliative care because of their poor performance, so they should be admitted to the palliative care unit.⁷ In a study on lung cancer, Bulbul et al stated that patients had unmet needs, and that they did not recover from pain and dyspnea.⁸ In a study by Maguire et al., it was determined that dyspnea affected the physical and psychosocial lives of patients with advanced lung cancer in the short term, and in the long term it caused hopelessness.⁹ A study carried out with 309 advanced lung cancer patients, stated that 89% of the patients had to apply to the hospital urgently regarding the problems they experienced, and this hospitalization rate had increased in the previous 3 months.¹⁰ Therefore, it is very important to

¹Nigde Bor State Hospital Orthopedic Service, Nigde Omer Halisdemir University Zubeyde Hanım School of Health, Nigde, Turkey
²Department of Internal Medicine, Nigde Omer Halisdemir University, Nigde, Turkey

Corresponding Author:
Hanife Ozcelik, Nigde Omer Halisdemir University Zubeyde Hanım School of Health, Department of Internal Medicine, Nigde 51000, Turkey.
Email: hanifeozcelik@hotmail.com
evaluate the symptoms and functional status of advanced lung cancer patients for the palliative care approach.

Assessment of hopelessness is also of critical importance in diseases with intensive clinical treatment such as lung cancer because hopelessness is a basic element of a depressive disorder and a predictor of suicidal tendencies. Clinical results have shown that hopelessness, demoralization, and a bad mood will negatively affect the quality of life of advanced cancer patients. However, hopelessness has been predicted to increase mortality in advanced cancer patients. Hannah Ball et al suggest that the psychological problem of patients with advanced lung cancer are related to uncertainty, hope, hopelessness, stigma, guilt, family and caregiver anxiety, physical distress of the disease, experience of tragedy caused by diagnosis, unexplained distress. In a systematic, it was discovered that patients with lung cancer experienced uncertainty about their future at a rate of 13–70% in the terminal period and had high levels of hopelessness. Therefore, it is highly important to determine the level of hopelessness experienced by advanced lung cancer patients.

In Turkey, advanced stage lung cancer patients are followed primarily in Thoracic clinics, Thoracic Intensive Care intensive care, and Thoracic Surgery clinics of state hospitals and medical faculties. They also receive health services from palliative care services in hospitals and from internal medicine clinics. There are palliative care services in state hospitals and medical faculties in Turkey. Especially after 2014, palliative care delivery and the number of beds increased rapidly in Turkey. However, it seems that the formation of a palliative care philosophy and trained health professionals and its integration into the health system will take time. In our country, as in the world, there are problems regarding the transition of advanced lung cancer patients to early palliative care. Bulbul et al determined that symptoms progressed and intensified in the advanced stages of lung cancer, and that palliative care was inadequate for most patients in Turkey. In another study, it was observed that patients with advanced non–small cell lung cancer had low quality of life, impaired psychological and physiological functions and could not receive adequate health care services.

In our study, we aimed to draw attention to the symptoms, performance, and hopelessness problems experienced by advanced lung cancer patients. We wanted to provide data on symptom levels, performance, hopelessness, and the connections between them in the diagnosis of transition to palliative care in these patients. Therefore, this study aimed to determine the symptom intensities, performance, and hopelessness levels of advanced lung cancer patients for the palliative care approach.

Materials and Methods

This research is a descriptive study carried out to determine the symptom intensities and hopelessness levels of advanced lung cancer patients for the palliative care approach. The study was conducted in the following departments of a medical faculty hospital in Turkey, where advanced lung cancer patients are frequently followed up and treated: Thoracic Surgery, Thoracic Surgery Intensive Care, Outpatient Chemotherapy Unit, Oncology, Oncology Outpatients’ Department and Chest Diseases Clinic.

The population of research consisted of 600 lung cancer patients who were being treated and followed up in the medical faculty clinics. For the research sample, 130 patients with advanced stage lung cancer who met the research criteria with a 95% confidence interval and a 5% margin of error were chosen using a population-specific sampling method. Patients who were over 18 years old, conscious, cooperative and oriented, without vision or hearing problems, able to communicate verbally, and diagnosed with stage III and IV lung cancer were included in the study.

A socio-demographic form, the Beck Hopelessness Scale, the Edmonton Symptom Assessment System Scale (ESAS), and the Karnofsky Performance Scale were used as data collection tools in the research. The socio-demographic form consisted of 20 questions prepared by the researcher by scanning the literature in order to determine the socio-demographic and disease-related characteristics of the patients. We used simple and easy-to-answer tools with validity and reliability. These tools are also frequently used in palliative care settings. The ESAS was developed to diagnose existing symptoms in patients with palliative cancer. Symptom monitoring was made by nurse with ESAS. The ESAS was developed by Bruera et al (1991) to diagnose the symptoms present in patients with advanced cancer. The validity and reliability of the ESAS in the Turkish population was tested by Usta et al in 2008, and the Cronbach alpha level of the scale was found to be >.70. The ESAS covers 9 symptoms seen in patients such as pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, well-being, and dyspnea and an alternative choice of “other symptom.” It is designed in a visual analog or numerical style, where the symptoms on the scale can be marked between 0 and 10. The total score of the ESAS varies between 0 and 100 points, and high scores obtained from the scale indicate a higher symptom level. After this assessment, advanced lung cancer patients’ high symptom load and intensity on the scale indicate that the patients have palliative care approach. The Karnofsky Performance Scale was developed by Karnofsky in 1948. This scale evaluates patients’ general and
functional status on a scale ranging from 0 to 100 points. In the scale, the patients’ symptoms, ability to perform daily activities, dependency status, and need for medical care are interrogated. A score of 100 points indicates normal health status, and zero points correspond to death. According to the results of the evaluation, patients within the 80–100% category do not need special care, and can continue their normal activities and work; patients in the 50–70% category can perform their personal care with help but cannot work, and patients in the 0–40% category cannot take care of themselves and their situation may quickly proceed to death.24

The Beck Hopelessness Scale (BHS) is a scale developed by Beck in 1974 to determine the level of hopelessness in patients with advanced cancer, and aims to measure the individual’s future expectations and pessimism levels. The scale consists of 20 items and statements expressing patients’ feelings and thoughts about the future.25 The validity and reliability of the Turkish scale was tested by Seber (1991) and Durak (1993).26 Patients are requested to mark the “correct” option for statements that apply to them and the “incorrect” option for statements that do not fit them. There are 11 “yes” and 9 “no” answer keys. Positive answers given to the following questions: 2, 4, 7, 9, 11, 12, 14, 16, 17, 18, and 20, score 1 point, and negative answers given to questions 1, 3, 5, 6, 8, 10, 13, 15, and 19 get zero points. There are 3 sub-scales. Items 1, 6, 13, 15, and 19 are about feelings relating to the future, and items 4, 7, 8, 14, and 18 are about expectations related to future. A high score obtained from BHS indicates high levels of hopelessness or negative expectations for the future.25,26

Research data were collected between January and July 2020. The purpose and method of the study were explained to the patients participating in the study, and their verbal and written consents were obtained. Research data were obtained by the researcher through using the socio-demographic form, Beck Hopelessness Scale, ESAS, and Karnofsky Performance Scale. The research data were evaluated using SPSS 22.00 (Statistical Program for Social Sciences) program package for analysis. The Shapiro–Wilk test was used to examine whether the data showed normal distribution. In evaluation of the data, the average scores of the scales were calculated using numbers, percentages, and frequencies. The Kruskal–Wallis, Mann–Whitney U and Pearson correlation tests were used in the analysis of the research data. The relationship between symptom burden and hopelessness was determined by the Pearson correlation test. The significance level was accepted as $P < .05$.

In order to evaluate the ethical suitability of the study, the approval of the Non-Interventional Research Ethics Committee of a local university (30.09.2019 - 25449) and the written permission of the Medical Faculty Hospital were obtained.

### Results

Table 1 shows the distribution of advanced lung cancer patients according to their socio-demographic characteristics.

| Socio-Demographical Characteristics | n   | %  |
|-----------------------------------|-----|----|
| Age (X ± SS)                      | 62.68 ± 8.867 |
| Gender                            |     |    |
| Female                            | 36  | 27.7|
| Male                              | 94  | 72.3|
| Marital status                    |     |    |
| Married                           | 115 | 88.5|
| Single                            | 7   | 5.4 |
| Living separately                 | 8   | 6.1 |
| Educational status                |     |    |
| Literate                          | 11  | 8.5 |
| Primary school graduate           | 54  | 41.5|
| Secondary school graduate         | 13  | 10.0|
| High school graduate              | 33  | 25.4|
| Faculty/School graduate           | 19  | 14.6|
| Job, occupational status          |     |    |
| Manual worker                     | 15  | 11.5|
| Office worker                     | 21  | 16.2|
| Self employed                     | 46  | 35.4|
| Retired                           | 18  | 13.9|
| Housewife                         | 25  | 19.3|
| Other                             | 5   | 3.8 |
| Working status                    |     |    |
| Not working                       | 116 | 89.2|
| Working part time                 | 9   | 6.9 |
| Full time work                    | 5   | 3.9 |
| Who do you live with at home?     |     |    |
| Alone                             | 5   | 3.8 |
| With my wife                      | 106 | 81.5|
| With children                     | 18  | 13.8|
| Other                             | 1   | 0.9 |
| Total                             | 130 | 100.0|

In the study, the mean age of the patients was 62.68 ± 8.867 years, 72.3% were males, 88.5% were married, 41.5% were basic school graduates, 89.2% were unemployed, and 81.5% were living with their spouses.

The distribution of patients with advanced stage lung cancer according to the variables related to the disease is given in Table 2. The average time since diagnosis of the disease in patients was 20.48 ± 21.547 months, and it was determined that 53.8% of them were at stage 3, 66.9% had developed metastases, 43.1% had undergone surgical treatment, and 80.8% had received chemotherapy, 50.0% radiotherapy, and 12.3% biotherapy. It was also identified that 56.3% of those who received biotherapy had also received tyrosine kinase inhibitors and 43.7% had received monoclonal antibodies. Karnofsky performance score was determined that .8% of the patients participating the study scored 30, 6.2% scored 40, 6.9% scored 50, 14.6% scored 60, and 71.5% scored 70, 80, or 90.

Table 3 shows the Edmonton Symptom Sub-Dimension and Total Scores that show the need for Palliative Care in...
Table 2. Distribution of Advanced Stage Lung Cancer Patients by Disease-Related Variables.

| Disease-Related Variables | n   | %   |
|---------------------------|-----|-----|
| **Stage of the disease**  |     |     |
| Grade 3                   | 70  | 53.8|
| Grade 4                   | 60  | 46.2|
| **Metastasis status**     |     |     |
| Yes                       | 87  | 66.9|
| No                        | 43  | 33.1|
| **Disease duration**      |     |     |
| Disease duration (months) | 20.48 ± 21.547 | |
| **Karnofsky Performance Score** |   |   |
| 30                        | 1   | 0.8 |
| 40                        | 8   | 6.2 |
| 50                        | 9   | 6.9 |
| 60                        | 19  | 14.6|
| 70-80-90                  | 93  | 71.5|
| **Status of receiving surgical treatment** | | |
| Yes                       | 56  | 43.1|
| No                        | 74  | 56.9|
| **Chemotherapy**          |     |     |
| Yes                       | 105 | 80.8|
| No                        | 25  | 19.2|
| **Radiotherapy**          |     |     |
| Yes                       | 65  | 50.0|
| No                        | 65  | 50.0|
| **Biotherapy**            |     |     |
| Yes                       | 16  | 12.3|
| No                        | 114 | 87.7|
| **Drugs for biotherapy areas** | | |
| Tyrosine kinase inhibitors | 9   | 56.3|
| Monoclonal antibodies     | 7   | 43.7|
| Total                     | 130 | 100|

Table 3. The Distribution of Patients With Advanced Stage Lung Cancer Edmonton Symptom Sub-Dimensions and Total Score/Score.

| Edmonton Symptom Total Score Average | X     | SD  | Min–Max |
|--------------------------------------|-------|-----|---------|
| Pain                                 | 4.46  | 2.68| 0–10    |
| Fatigue                              | 5.46  | 2.12| 0–9     |
| Nausea                               | 3.15  | 2.84| 0–9     |
| Depression                            | 3.65  | 2.88| 0–10    |
| Anxiety                               | 3.38  | 2.84| 0–10    |
| Drowsiness                            | 5.01  | 2.45| 0–10    |
| Anorexia                              | 5.40  | 2.59| 0–10    |
| Well-being                            | 5.69  | 1.87| 2–9     |
| Dyspnea                               | 4.49  | 2.46| 0–9     |
| Constipation                          | 2.45  | 2.53| 0–8     |
| Cough                                 | 4.02  | 2.41| 0–8     |
| ESAS symptom total score             | 47.17 | 19.03| 6–96    |

ESAS, Edmonton Symptom Assessment System; SD, standard deviation.

Advanced Stage Lung Cancer Patients and the Hopelessness Scores taken from the Beck Hopelessness Scale. Among the symptoms that patients will apply to the palliative care approach, the most frequent and the highest ones were fatigue with 5.46 ± 2.12, worsening general health and well-being with 5.69 ± 1.87, and anorexia with 5.40 ± 2.59. These were followed by drowsiness with 5.01 ± 2.45, dyspnea with 4.49 ± 2.68, cough with 4.02 ± 2.41, depression with 3.65 ± 2.88, anxiety with 3.38 ± 2.84, nausea with 3.15 ± 2.84, and constipation with 2.45 ± 2.53, and the mean total score of symptoms was 47.17 ± 19.03. Among the sub-dimensions of hopelessness, the mean score for feelings and expectations about the future was found to be 1.40 ± 1.66. For loss of motivation, it was 3.43 ± 2.41, and for hope it was 2.05 ± 1.75. The hopelessness total score was 7.41 ± 6.01. Table 4 demonstrates the relationship of the patients with advanced stage lung cancer to the Edmonton Symptom Total Score, the Hopelessness Total Score and Sub-Dimensions, the Karnofsky Performance Score, their age and the months since the disease was diagnosed. According to this table, there was a positive correlation between patients’ hopelessness level and the symptom burden (P < .05). There was a negative correlation between Karnofsky performance scores and the total EDS symptom score (P < .05). A statistically positive correlation was found between scores obtained from feelings and expectations about the future, loss of motivation and hope, which are among the sub-dimensions of hopelessness, and the total EDS symptom score, age, and months since diagnosis; however, there was a negative relationship with the Karnofsky performance score (P < .05).

Table 5 shows the distribution of the socio-demographic characteristics of the advanced stage lung cancer patients according to the Edmonton Symptom Total Score, Karnofsky Performance, Hopelessness Total and Sub-Dimensional Score Averages. A significant difference was detected between gender and the hopelessness total score, the hopelessness sub-dimensions scores, the loss of motivation score, and the hope score (P < .05). It was also found that women’s hopelessness levels were higher than men’s, women’s loss of motivation rate was higher than men’s, and there was a statistically significant difference between groups. A significant difference was found between employment status and the hopelessness sub-dimensions, the hope and total EDS symptom score, and the patients’ Karnofsky performance (P < .05). A significant difference was found in the patients between the stage of the disease and the hopelessness sub-dimensions, feelings and expectations about the future, loss of motivation, hope and hopelessness total score, EDS symptom total score, and Karnofsky performance (P < .05). There was also a significant difference between the patients’ metastatic status and their feelings and expectations about the future, loss of motivation, hope and hopelessness total score, and Karnofsky performance (P < .05). A significant difference was found between the use of analgesics and feelings and expectations about the future loss of motivation, hope and hopelessness total score, EDS symptom total score, and Karnofsky performance (P < .05).
Among the symptoms that patients will apply to the palliative care approach, the most frequent and highest were as follows: fatigue, worsening in general health and well-being, and anorexia symptoms, these were followed by drowsiness, dyspnea, pain, cough, depression, anxiety, nausea, constipation, and symptom total mean score with 47.17 ± 19.03. Similar to our study in the literature, fatigue, deterioration in general health, loss of appetite, and dyspnea are the most common symptoms. In our study, unlike the literature, pain was seen at lesser rates. However, the symptom burden of our patients that needed to be eliminated was found to be high. Yogananda et al.27 discovered that 89.5% of advanced lung cancer patients experienced fatigue, 85.7% suffered from dyspnea, 85% anorexia, 82% pain, 85.6% feeling bad, 81.1% anxiety, 78.9% depression, 49.6% nausea, and 29.3% drowsiness.27 Sung et al.5 found that advanced lung cancer patients experienced fatigue, cough, and dyspnea.5 Tanaka et al.28 determined that advanced lung cancer patients suffered from dyspnea the most, followed by fatigue and pain.28 Potter et al. reported that lung cancer patients experienced pain most frequently.29 Kapo found that patients with advanced lung cancer most often experience pain, dyspnea, and fatigue; those symptoms affected 65% of the patients.6 Bülbül et al. stated in a study carried out on lung cancer that patients had unmet needs and pain and dyspnea, and did not improve.8

It was suggested that hopelessness experienced by advanced cancer patients admitted to palliative care would affect mortality from the disease.14,15 In our study, we found in patients with advanced lung cancer that among the hopelessness sub-dimensions, the score for feelings and expectations about the future was found to be 47.17 ± 19.03. Similar to our study, there are studies in the literature that found mild to moderate hopelessness, as well as studies that found hopelessness high, especially in the terminal period. In a study carried out by Bozdogan et al, lung cancer patients, the score for the hopelessness sub-dimensions of feelings and expectations about the future was found to be 3.87 ± 1.19, for motivation loss 3.56 ± 1.83, and for hope 1.41 ± 1.47, and the total score of hopelessness was 5.84 ± 3.55. 33 Maguire et al. found that patients with lung cancer experienced uncertainty about their future at a rate of 13–70% in the terminal period and had high levels of hopelessness.9 Mystakidou et al.31 determined that 70.6% of cancer patients diagnosed with lung cancer and already receiving palliative care had poor performance, and a mild hopelessness level according to ECOG performance.31 Ball et al. discovered that patients with mesothelioma and lung cancer experienced multifaceted and complex psychological distress.10 Rodin et al.32 found that patients with Stage IV gastrointestinal and lung cancer had a Karnofsky performance scale of 81.55 and a low level of hopelessness.32

In our study, as the symptom burden of patients with advanced lung cancer increased and as their Karnofsky performance decreased, their hopelessness level further increased. A positive correlation was found between hopelessness levels and symptom burden and a negative correlation was found with their performance. Similar to the literature, it was determined in our study that the symptoms could increase the level of hopelessness even more. In a study by Maguire et al., it was determined that dyspnea affected the physical and psychosocial lives of patients with advanced lung cancer in the short term, and in the long term it caused hopelessness.9 In a study by Steffen et al.33 where a majority of patients had stage IV non–small cell lung cancer, they found that patients with high hope levels experienced less fatigue and pain.33 Berendes et al.34 found that as hope decreased, pain, fatigue, cough, and depression increased.34 It has been shown in the literature that the level of hope can be increased by reducing the burden of symptoms. These findings once again showed that hopelessness should be screened in advanced lung cancer patients.
In our study, we detected that as age and months since diagnosis increased and the disease progressed in patients with advanced stage lung cancer, their hopelessness level increased and their performance decreased. A significant difference was found between gender and hopelessness and sub-dimension scores. Women’s hopelessness levels and loss of motivation rates were higher than those of men. A significant difference was found between education and employment status, stage of disease, presence of metastasis, use of analgesics and total and sub-dimension scores. Similarly, in a study by Mystakidou et al, there was a positive relationship between hopelessness levels of patients with lung cancer and depression, age and gender, whereas there was a negative relationship between performance level and hopelessness level. Temel et al found that the age and gender of cancer patients can change both their cancer experiences and palliative care needs. Fadiloglu et al reported that there was a significant difference between the hopelessness levels of breast cancer patients over 60 years of age, and that the level of hopelessness increased as patients’ age increased. Differently, Bozdogan Yesilot et al found no significant difference between the age of lung cancer patients and the level of hopelessness. Bener et al stated that there was

| Table 5. Distribution of Socio-Demographic Characteristics of Advanced Stage Lung Cancer Patients by Edmonton Symptom Total Score, Karnofsky Performance, Hopelessness Total and Sub-Dimensional Score Averages. |
|---------------------------------------------------------------|
| **Feelings and Expectations About the Future** | **Loss of Motivation** | **Hopelessness Total Score** | **ESAS Symptom Total Score** | **Patient’s Karnofsky Performance** |
| Gender | | | | | |
| Female | 74.85 | 80.08 | 76.42 | 78.63 | 69.53 | 66 |
| Male | 61.92 | 59.91 | 61.32 | 60.47 | 63.96 | 65.31 |
| p* | .061 | **.005** | **.037** | **.013** | .450 | .922 |
| Marital status | | | | | |
| Married | 64.26 | 63.9 | 64.52 | 64 | 64.5 | 67.5 |
| Single | 71.79 | 66.57 | 63.29 | 69.71 | 54.21 | 60.43 |
| Living separately | 77.88 | 87.5 | 81.5 | 83.31 | 89.81 | 41.13 |
| p** | .508 | **.209** | **.447** | **.353** | .132 | .125 |
| Educational status | | | | | |
| Literate | 98.5 | 107.14 | 109.36 | 109.64 | 99.68 | 35.27 |
| Primary school graduate | 59.6 | 58.83 | 60.57 | 59.06 | 70.8 | 58.19 |
| Secondary school graduate | 76.85 | 89.42 | 83.69 | 83.42 | 81.73 | 59 |
| High school graduate | 67.06 | 61.94 | 61.94 | 63.5 | 51.05 | 77.74 |
| Faculty/college graduate | 52.68 | 50.16 | 47.84 | 4.47 | 44.66 | 86.97 |
| p** | .004 | **.000** | **.000** | **.000** | **.000** | **.000** |
| Professional status | | | | | |
| Manual worker | 68.9 | 63.77 | 66.6 | 65.37 | 58.2 | 60.3 |
| Office worker | 62.48 | 59.74 | 64.19 | 61.36 | 58.05 | 78.9 |
| Self-employed | 65.49 | 64.84 | 60.89 | 64.21 | 68.75 | 62.42 |
| Retired | 44.08 | 51.69 | 55 | 49.83 | 58.75 | 69.72 |
| Housewife | 76.88 | 82.32 | 81.36 | 80.7 | 78.14 | 59.96 |
| Other (artisan, cook, warden) | 88.3 | 66.5 | 68.6 | 75.6 | 49.9 | 68.6 |
| p** | **.04** | .133 | .23 | .159 | .308 | .53 |
| Working status | | | | | |
| Not working | 67.21 | 66.42 | 68 | 67.24 | 69.88 | 61.47 |
| Part time | 61.83 | 67.83 | 56.89 | 63.83 | 37.56 | 84.11 |
| Full time | 32.5 | 39.9 | 23 | 28.1 | 14.2 | 125.5 |
| p** | .092 | **.277** | **.022** | **.072** | **.000** | **.000** |
| Living with whom? | | | | | |
| Alone | 43.2 | 34.1 | 28.2 | 34.3 | 30.5 | 84.9 |
| With my wife | 64.24 | 64.19 | 64.71 | 63.87 | 64.64 | 68.45 |
| With children | 80.94 | 84.14 | 81.56 | 84.81 | 80.75 | 43.47 |
| Other (family, mother, father, friend) | 32.5 | 26 | 47 | 46.5 | 57.5 | 52 |
| p** | **.09** | **.021** | **.032** | **.033** | **.061** | **.029** |

p*: Mann–Whitney u test P<.05, p**: Kruskal–Wallis Test.
a significant difference between the education level of breast cancer patients and their level of hopelessness.37 Cam et al suggested that breast cancer patients can show different and complex behavioral and emotional responses at every stage of the disease process. The reason for these reactions was the different sociocultural structure of the region where patients lived, and they were affected by this sociocultural structure.38

As a result, it was determined that fatigue, deterioration in general health, and loss of appetite were the most common symptoms in advanced lung cancer patients and the symptom burden of the patients was high. There was a positive correlation between patients’ hopelessness level and the symptom burden and a negative correlation between performance scores. It was determined that the symptom burden of patients with advanced lung cancer increased and as their Karnofsky performance decreased, their hopelessness level further increased. A significant difference was found between the patients’ age, months since diagnosis, gender, education and employment status, stage of the disease, presence of metastases and analgesic use, and hopelessness scores.

Acknowledgments
The authors thank all patients for their willingness to participate.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval
This study was in accordance with the principles of Declaration of Helsinki and all subjects provided written informed consent. The study protocol was accepted by the Nigde University Ethics Committee (27.09.2019/10).

ORCID iD
Hanife Ozcelik https://orcid.org/0000-0001-6137-3976

References
1. Institute National Du Cancer. Les chiffres du cancer en France. 2019. https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers. Accessed May 11, 2020.
2. Smith TJ, Temin S, Alesi ER, et al. American society of clinical oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880-887.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Intern J Cancer. 2001;94(2):153-156.
4. Osse BHP, Vernooij-Dassen MJFJ, De Vree BPW, Schadé E, Grol RPTM. Assessment of the need for palliative care as perceived by individual cancer patients and their families. Cancer. 2000;88(4):900-911.
5. Sung MR and Patel MV et al. Evolution of symptom burden of advanced lung cancer over a decade. Clin Lung Cancer. 2017;18(3):274-280.
6. Kapo JM and Akgün KM. Integrating palliative care into the care of patients with advanced lung cancer. Cancer J. 2015;21(5):434-439.
7. Wilcock A, Crosby V, Hussain A, et al. Lung cancer diagnosed following an emergency admission: Mixed methods study of the management, outcomes and needs and experiences of patients and carers. Respir Med. 2016;114(2):38-45.
8. Bülbüll Y, Özlu T, Arinc S, et al. Assessment of palliative care in lung cancer in turkey. Med Princ Pract: Intern J Kuwait Univer-sity, Health Sci Centre. 2017;26(1):50-56.
9. Maguire R, Papadopoulos C, Kotronoulas G, Simpson MF, McPhelim J, Irvine L. A systematic review of supportive care needs of people living with lung cancer. Eur J Oncol Nurs. 2013;17(4):449-464.
10. Lafitte C, Etienne-Mastroianni B, Fournel C, Natoli L, Foucaut AM, Girard N. Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer. Lung Cancer. 2018;124(1):143-147.
11. Mystakidou K, Tsilika E, Parpa E, et al. Illness-related hopelessness in advanced cancer: Influence of anxiety, depression, and preparatory grief. Arch Psychiatr Nurs. 2009;23(2):138-147.
12. Kissane DW, Clarke DM, Street AF. Demoralization syndrome - A relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17(1):12-21.
13. McLeod JE, Clarke DM, Smith GC, Trauer T, Kissane DW. A review of psychosocial aspects of motor neurone disease. J Palliat Care. 2005;21(3):173-179.
14. Eversen SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med. 1996;58(2):113-121.
15. Lehto U-S, Ojanen M, Dyba T, Aromaa A, Kellokumpu-Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res. 2007;63(1):9-15.
16. Kutluk T, Ahmed F, Cemaloğlu M, et al. Progress in palliative care for cancer in turkey: A review of the literature. Ecancermedicalscience. 2021;151321:1-84.
17. Yıldırım B, Ö T. Evaluation of cancer patients admitted to the emergency department within one month before death in Turkey: What are the Problems Needing Attention? Asian Pac J Cancer Prev APJCP. 2014;15:349-353.
18. Gultekin Z, Pınar G, Pınar T, et al. Health-related quality of life and health care services expectations of the patients with lung cancer. Intern J Hematology and Oncology. 2008;2(18):99-106.
19. Topkaya O. Studying the palliative care needs of cancer patients and patients’ and their families’ information and expectations related to palliative care. Okan University Health Sciences InstitutePostgraduate Thesis. 2018;30(5):44-45.
20. Osse BHP, Vernooij-Dassen MJFJ, Schadé E, Grol RPTM. The problems experienced by patients with cancer and their needs for palliative care. *Support Care Cancer*. 2005;13:722-732.

21. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: Toward individualized care for patients with advanced cancer. *J Clin Oncol*. 2011;29(6):755-760.

22. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The edmonton symptom assessment system (ESAS): A simple method for the assessment of palliative care patients. *J Palliat Care*. 1991;7(2):6-9.

23. Yesilbalkan O, Ozkutuk N, Karadakovan A, Turgut T, Kazgan B. Validity and reliability of the edmonton symptom assessment scale in turkish cancer patients. *Turk J Cancer*. 2008;38(2):62-66.

24. Péus D, Newcomb N, Hofer S. Appraisal of the karnofsky performance status and proposal of a simple algorithmic system for its evaluation. *BMC Medical Informatics and Decision Making*. 2013;13(13):72-77.

25. Seber G, Dilbaz N, Kaptanoglu C, Tekin D. Hopelessness Scale: validity and reliability. *J Crisis*. 1993;1(3):139-142.

26. Durak A, Palabiyikoglu R. Beck Umutsuzluk. *Kriz Dergisi*. 1994;2(2):311-319.

27. Yogananda MN, Muthu V, Prasad KT, Kohli A, Behera D, Singh N. Utility of the revised edmonton symptom assessment system (ESAS-r) and the patient-reported functional status (PRFS) in lung cancer patients. *Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*. 2018;26(13):767-775.

28. Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. *J Pain Symptom Manag*. 2002;23(5):417-423.

29. Potter J, Higginson IJ. Pain experienced by lung cancer patients: A review of prevalence, causes and pathophysiology. *Lung Cancer*. 2004;43(3):247-257.

30. Bozdogan Yesilot S, Oztunc G, Oztunc G, Yesil Demirci P, Inel Manav A, Paydas S. The evaluation of hopelessness and perceived social support level in patients with lung cancer. *Life: I J Health and Life-Sciences*. 2017;3(2):88-105.

31. Mystakidou K, Tsilika E, Parpa E, Pathiaki M, Galanos A, Vlahos L. The relationship between quality of life and levels of hopelessness and depression in palliative care. *Depress Anxiety*. 2008;25(9):730-736.

32. Rodin G, Lo C, Mikulincer M, Donner A, Gagliese L, Zimmernann C. Pathways to distress: The multiple determinants of depression, hopelessness, and the desire for hastened death in metastatic cancer patients. *Soc Sci Med*. 2009;68(3):562-569.

33. Steffen LE, Cheavens JS, Vowles KE, et al. Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients. *Support Care Cancer*. 2019;28:827-835.

34. Berendes D, Keefe FJ, Somers TJ, Kothadia SM, Porter LS, Cheavens JS. Hope in the context of lung cancer: relationships of hope to symptoms and psychological distress. *J Pain Symptom Manag*. 2010;40(2):174-182.

35. Temel JS, Greer JA, El-Jawhari A, et al. Effects of early integrated palliative care in patients with lung and gi cancer: A randomized clinical trial. *J Clin Oncol*. 2017;35(8):834-841.

36. Fadiloglu C, Cantilav S, Yildirim YK, Tokem Y. In women with breast cancer the relationship between their hopelessness levels and the coping behaviors. *J Ege University Higher School of Nursing*. 2006;22(2):147-160.

37. Bener A, Alsulaiman R, Doodson L, Agathangelou T. Depression, hopelessness and social support among breast cancer patients: in highly endogamous population. *Asian Pac J Cancer Prev APJCP*. 2017;18(7):1889-1896.

38. Cam O, Saka S, Gümüs AB. Examining the factors affecting social adaptation of breast cancer patients. *Breast Heal J*. 2009;5(2):73-81.